DSCSA Enforcement in 2026: Building Interoperable Drug Supply Chain Systems

The Drug Supply Chain Security Act represents the most significant regulatory transformation of the U.S. pharmaceutical distribution system in decades. Signed into law in 2013, the DSCSA established a ten-year roadmap to create an electronic, interoperable system capable of tracing prescription drugs at the package level throughout the entire supply chain, from manufacturer to dispenser. The ultimate objective is straightforward in concept but extraordinarily complex in execution: every stakeholder in the pharmaceutical supply chain must be able to trace any individual drug package from its point of manufacture through every change of ownership to the point of dispensing, using standardized electronic data exchanged between interoperable systems.

For pharmaceutical IT leaders, the DSCSA compliance challenge extends far beyond implementing a serialization system on a packaging line. Full compliance requires an end-to-end technology architecture that encompasses serialization at the point of manufacture, aggregation of serialized units into cases and pallets, generation and exchange of Electronic Product Code Information Services event data with every trading partner, verification of product identifiers upon receipt, and the ability to respond to trace requests from the FDA within twenty-four hours. This is a supply chain data infrastructure project of enormous scope, and organizations that have underestimated its complexity are now confronting enforcement timelines with incomplete implementations.

This article examines the current state of DSCSA enforcement in 2026, the technical requirements for electronic interoperable traceability, the IT architecture decisions that pharma organizations must make, and the strategic considerations that IT leaders should weigh as they navigate the final phases of compliance implementation.

The DSCSA Mandate: A Decade in the Making

The DSCSA was enacted as Title II of the Drug Quality and Security Act in November 2013, replacing a patchwork of state-level drug pedigree laws with a unified federal framework. The legislation established phased requirements that would progressively build the capabilities needed for full electronic interoperable traceability over a ten-year period. The initial phases focused on product identification requirements, mandating that manufacturers, wholesale distributors, repackagers, and dispensers exchange transaction information, transaction history, and transaction statements when products change ownership. These early phases relied primarily on lot-level tracking and could be satisfied through relatively simple electronic data interchange or paper-based documentation.

The foundational requirement for product serialization took effect for manufacturers in November 2018, requiring that each individual package of prescription drug product bear a unique product identifier encoded in a two-dimensional data matrix barcode. This product identifier, structured according to GS1 standards, includes the National Drug Code, a unique serial number, the lot number, and the expiration date. Wholesale distributors were subsequently required to accept and handle only serialized products, and dispensers were required to be able to verify product identifiers at the package level.

The November 2024 Milestone

The culminating requirement of the DSCSA was scheduled to take effect on November 27, 2023, but was delayed by the FDA to November 27, 2024, through a series of guidance documents and enforcement discretion announcements. This final phase mandated the implementation of electronic interoperable traceability, requiring all trading partners to exchange transaction information and transaction statements electronically at the package level using systems that are interoperable across the supply chain. The shift from lot-level to package-level tracking represented an exponential increase in data volume and system complexity, requiring every transaction to reference individual serial numbers rather than lot-level identifiers.

The industry’s readiness for this milestone varied enormously. Large pharmaceutical manufacturers with established serialization programs and dedicated DSCSA compliance teams were generally better positioned, though many still faced challenges in achieving full electronic data exchange with all of their trading partners. Mid-size and smaller manufacturers, generic drug companies, contract manufacturing organizations, and many wholesale distributors and dispensers faced significant gaps in their technical readiness, system integration maturity, and trading partner connectivity.

Legislative Intent and Public Health Objectives

Understanding the legislative intent behind the DSCSA is important context for IT leaders because it informs how the FDA approaches enforcement and where the agency is likely to focus its compliance expectations. The primary objectives of the DSCSA are to protect consumers from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful; to improve detection and removal of potentially dangerous drugs from the supply chain; to improve the efficiency and effectiveness of drug recalls; and to create the data infrastructure needed for the FDA to respond to drug supply chain emergencies. These public health objectives mean that the FDA’s enforcement priorities will be shaped by the extent to which compliance gaps create risks to patient safety, not merely by the technical completeness of electronic data exchange implementations.

2026 Enforcement Reality: What Has Changed

The FDA’s approach to DSCSA enforcement has evolved significantly from the original statutory timeline, reflecting the practical reality that the industry was not uniformly ready to achieve full electronic interoperable traceability by the November 2024 deadline. Understanding the current enforcement landscape is essential for IT leaders who must calibrate their compliance investments against realistic regulatory expectations.

Phased Enforcement and Stabilization Period

The FDA announced a phased approach to enforcement that provides a stabilization period during which the agency exercises enforcement discretion for certain requirements while companies continue to build out their traceability capabilities. During this stabilization period, the FDA has indicated that it will focus its enforcement efforts on the foundational elements of compliance: product serialization, the ability to verify product identifiers, and the exchange of transaction information with direct trading partners. The agency has been less prescriptive about requiring full end-to-end interoperable traceability across the complete supply chain during the stabilization period, recognizing that achieving full interoperability requires coordination among trading partners with varying levels of technical maturity.

However, the stabilization period is not an indefinite reprieve. The FDA has made clear through public statements and industry engagements that it expects companies to be making demonstrable progress toward full compliance and that the enforcement discretion will narrow over time. By 2026, organizations are expected to have functional serialization and aggregation capabilities, to be exchanging electronic transaction data with their direct trading partners at the package level, and to be actively working toward the interoperability and data completeness requirements that represent the full vision of the DSCSA.

Enforcement Actions and Warning Signals

Although the FDA has exercised enforcement discretion broadly during the stabilization period, there are clear boundaries to that discretion. The agency has indicated that it will not exercise enforcement discretion for organizations that have made no effort to comply, that continue to ship non-serialized products, or that are unable to respond to verification requests for suspect or illegitimate products. The verification requirements are particularly important because they represent the immediate patient safety function of the DSCSA: when a trading partner identifies a suspect product, the manufacturer must be able to verify the product identifier within a defined timeframe to determine whether the product is legitimate. Failure to maintain this verification capability represents a direct risk to patient safety and is unlikely to be subject to extended enforcement discretion.

Anticipated Tightening of Enforcement

Industry observers and regulatory counsel widely expect the FDA to progressively tighten DSCSA enforcement throughout 2026 and into 2027. The agency has invested significant resources in building its own systems for collecting and analyzing DSCSA data, and it has established a dedicated Drug Supply Chain Security program within the Office of Pharmaceutical Quality. As the agency’s own analytical capabilities mature, it will be increasingly positioned to identify compliance gaps across the supply chain and to take targeted enforcement actions against organizations that are materially non-compliant. IT leaders should plan their DSCSA compliance programs with the assumption that the current enforcement discretion environment is temporary and that the regulatory expectation for full electronic interoperable traceability will be enforced with increasing rigor over the coming years.

Electronic Interoperable Traceability Explained

Electronic interoperable traceability is the core technical concept of the DSCSA’s final phase, and it represents a significant departure from the lot-level tracking and paper-based transaction documentation that characterized the earlier phases. Understanding what this requirement actually entails at a technical and operational level is essential for making sound IT investment decisions.

Package-Level Tracking

The fundamental shift in the DSCSA’s final phase is the move from lot-level to package-level tracking. Under lot-level tracking, transaction records identify products by their National Drug Code and lot number, meaning that all packages within a lot are treated as interchangeable and the transaction record does not distinguish between individual packages. Under package-level tracking, each individual package is identified by its unique product identifier, which includes a serial number that is unique to that specific package. Every transaction record must reference the specific serial numbers of the packages involved in the transaction, creating a complete chain of custody for each individual package from manufacturer to dispenser.

The implications of this shift for IT infrastructure are profound. The data volume increases by orders of magnitude because every transaction must reference individual serial numbers rather than lot-level identifiers. A single shipment that would have generated a handful of lot-level transaction records now generates thousands or tens of thousands of package-level records, each referencing a unique serial number with associated transaction data. The storage, processing, and exchange of this data at scale requires enterprise-grade systems with high throughput, reliable message delivery, and robust data management capabilities.

Interoperability Requirements

The interoperability requirement of the DSCSA means that the electronic systems used by different trading partners must be able to exchange traceability data in a standardized format that can be processed by the receiving system without manual intervention or custom translation. This is not merely a technical standard requirement; it is a business process transformation requirement that demands coordinated adoption of common data standards, communication protocols, and data exchange agreements across the entire supply chain. Interoperability means that a manufacturer’s serialization and traceability system must be able to generate transaction data that can be received and processed by any wholesale distributor’s system, and the distributor’s system must be able to generate forwarding transaction data that can be received and processed by any dispenser’s system, all without bespoke point-to-point integration between each trading partner pair.

Transaction Information and Transaction Statements

The DSCSA defines specific data elements that must be exchanged as part of electronic interoperable traceability. Transaction information includes the proprietary or established name of the product, the strength and dosage form, the National Drug Code, the container size, the number of containers, the lot number, the transaction date, the shipment date, and the names and addresses of the parties involved in the transaction. Under package-level tracking, this information must be associated with the specific serial numbers of the packages involved. Transaction statements are attestations by the transferring party that the transaction data is accurate, that the product was not purchased from entities listed on the FDA’s exclusion list, and that the product was handled in accordance with applicable requirements. The electronic exchange of both transaction information and transaction statements must be completed for each change of ownership, creating a continuous electronic record of each package’s journey through the supply chain.

Technical Requirements for Compliance

Achieving DSCSA compliance requires a technology stack that spans multiple functional domains, from packaging line serialization through enterprise data management to inter-company electronic data exchange. Each layer of this technology stack presents distinct technical challenges and integration requirements.

Serialization at the Packaging Line

Product serialization begins at the packaging line, where unique product identifiers must be generated, printed on packaging in a GS1 DataMatrix format, verified by vision inspection systems, and recorded in the serialization system. The serialization process must be integrated into the packaging line control system to ensure that every package that exits the line has a verified, readable product identifier and that the corresponding serial number data is captured in the enterprise serialization repository. The technical requirements include high-speed printing and verification equipment capable of maintaining production line speeds, serialization software that manages serial number generation, allocation, and status tracking, and integration with packaging line control systems to ensure that packages with unreadable or unverifiable product identifiers are rejected from the production process.

Aggregation and Hierarchy Management

Aggregation is the process of establishing parent-child relationships between serialized packages and the cases, bundles, and pallets that contain them. When serialized packages are packed into a case, the aggregation system records which specific serial numbers are contained within that case and assigns a serial shipping container code to the case. When cases are palletized, the system records which cases are on each pallet and assigns a pallet-level identifier. This aggregation hierarchy is essential for efficient distribution because trading partners need to be able to receive and verify shipments at the case or pallet level rather than scanning every individual package. The aggregation data must be maintained accurately through every handling step, and any changes to the hierarchy, such as when cases are broken for split shipments, must be recorded as disaggregation events that update the hierarchy data.

Master Data Management

DSCSA compliance depends on accurate and consistent master data across all trading partners. Product master data, including National Drug Codes, product descriptions, package configurations, and GS1 Global Trade Item Numbers, must be aligned between the manufacturer’s systems, the trading partner’s systems, and the data exchanged in transaction records. Location master data, including Global Location Numbers that identify facilities and trading partner entities, must be accurate and consistently used in transaction records to ensure that the parties to each transaction are correctly identified. Master data inconsistencies between trading partners are one of the most common sources of transaction processing failures and verification errors, and resolving these inconsistencies requires coordinated master data governance across the supply chain.

GS1 Standards and the EPCIS Foundation

The GS1 standards framework is the backbone of DSCSA interoperability. The FDA has identified GS1 standards as the foundation for the standardized data exchange required by the DSCSA, and practical compliance implementation is built almost entirely on GS1 identification, data capture, and data sharing standards.

GS1 Identification Standards

The GS1 identification standards provide the numbering systems used to uniquely identify products, locations, and logistics units throughout the supply chain. The Global Trade Item Number identifies a specific product configuration at the package level. The Serial Shipping Container Code identifies individual logistics units such as cases and pallets. The Global Location Number identifies legal entities and physical locations involved in supply chain transactions. These identification standards ensure that every product, every location, and every logistics unit has a globally unique identifier that can be referenced consistently across all trading partner systems. The use of standardized identifiers is what makes interoperability possible, because any system that understands GS1 identifiers can process transaction data from any other GS1-compliant system without custom translation.

EPCIS: The Data Exchange Standard

The Electronic Product Code Information Services standard is the GS1 data sharing standard that provides the framework for exchanging supply chain event data between trading partners. EPCIS defines a common vocabulary for describing supply chain events in terms of four dimensions: what happened (the event type), when it happened (the event timestamp), where it happened (the location), and why it happened (the business context). The EPCIS standard defines several event types that are directly relevant to DSCSA compliance. Object events record actions performed on specific objects, such as commissioning a serial number or decommissioning a product. Aggregation events record the packing and unpacking of items into containers. Transaction events associate specific products with business transactions such as purchase orders and shipments. Transformation events record manufacturing processes that consume inputs and produce outputs.

The EPCIS standard, combined with the Core Business Vocabulary standard that defines the business context codes used in EPCIS events, provides a complete framework for describing any pharmaceutical supply chain transaction in a standardized, machine-readable format. When a manufacturer ships product to a wholesale distributor, the shipment is recorded as a series of EPCIS events: aggregation events documenting the packing of serialized units into cases and cases onto pallets, a shipping event documenting the departure of the shipment from the manufacturer’s facility, and transaction events associating the serialized products with the specific purchase order and shipment. The wholesale distributor records corresponding receiving events, and the entire transaction is documented in a standardized format that creates an unbroken chain of custody from manufacturer to distributor.

GS1 Digital Link and Future Directions

The GS1 Digital Link standard represents the next evolution of GS1 identification, encoding product identifiers in a web URI format that can be resolved to provide access to product information, traceability data, and authentication services. While the Digital Link standard is not yet required for DSCSA compliance, it signals the direction of travel for pharmaceutical product identification and has implications for IT architecture decisions being made today. Organizations that design their serialization and traceability systems with awareness of the Digital Link standard can position themselves for future capabilities, such as consumer-facing product verification and direct-to-patient traceability, without requiring fundamental architecture changes.

Trading Partner Connectivity and Verification

The most operationally challenging aspect of DSCSA compliance is not implementing the technology within a single organization but establishing reliable electronic data exchange with the dozens, hundreds, or thousands of trading partners with whom the organization conducts business. Each trading partner relationship requires technical connectivity, data format alignment, business process coordination, and ongoing operational management.

Connectivity Models

There are several models for establishing electronic data exchange between trading partners for DSCSA compliance. Direct point-to-point connections between trading partner systems provide the most control but require establishing and maintaining a separate connection with every trading partner. Network-based models, in which trading partners connect to a shared interoperability network that routes data between members, reduce the number of connections each organization must maintain but introduce dependency on the network operator. Hybrid models combine direct connections with major trading partners with network-based connectivity for smaller or less frequent trading relationships. The choice of connectivity model has significant implications for IT architecture, operational complexity, and the ability to scale trading partner onboarding to meet compliance timelines.

Verification Router Services

Product identifier verification is a core DSCSA requirement that enables trading partners to confirm the legitimacy of products they receive. When a distributor or dispenser receives a product and wants to verify its authenticity, it must be able to query the manufacturer’s verification system to confirm that the serial number on the product matches the manufacturer’s records. The FDA’s approach to verification has centered on the concept of verification router services, which act as intermediaries that route verification requests from downstream trading partners to the appropriate manufacturer’s verification system. This routing function is necessary because a distributor that handles products from hundreds of manufacturers cannot maintain direct verification connections with each one. Verification router services accept verification requests, identify the manufacturer based on the product identifier, route the request to the manufacturer’s verification system, and return the verification response to the requesting party.

Trading Partner Onboarding

The process of onboarding trading partners for electronic data exchange is time-consuming and resource-intensive. Each trading partner relationship requires agreement on the data exchange format and communication protocol, technical setup and testing of the connectivity mechanism, master data alignment to ensure that product identifiers, location identifiers, and business codes are consistent between systems, business process alignment to ensure that the timing and content of data exchanges match the physical product flow, and operational procedures for handling exceptions, errors, and data quality issues. For large pharmaceutical manufacturers with hundreds of wholesale distributor and dispenser trading partners, the trading partner onboarding effort is a multi-year program that requires dedicated project resources and structured program management. The pace of trading partner onboarding is often the constraining factor on overall DSCSA compliance timelines, because it depends not only on the manufacturer’s own readiness but on the readiness of each trading partner.

IT Architecture for DSCSA Compliance

The IT architecture required for comprehensive DSCSA compliance spans multiple system layers and must integrate with existing enterprise systems, manufacturing systems, and external trading partner systems. Designing this architecture requires careful consideration of scalability, reliability, integration complexity, and long-term maintainability.

Enterprise Serialization Platform

The enterprise serialization platform serves as the central system of record for all serialized product data and forms the core of the DSCSA compliance architecture. This platform manages the lifecycle of every serial number from generation through commissioning, aggregation, shipping, and ultimately decommissioning or dispensing. The platform must handle the full volume of serial numbers generated across all manufacturing and contract manufacturing sites, maintain accurate status information for every serial number, and support the query performance needed for verification responses and trace request fulfillment. The enterprise serialization platform must integrate with packaging line serialization systems at each manufacturing site, with the ERP system for order and shipment data, with the warehouse management system for logistics data, and with the trading partner connectivity layer for external data exchange.

Cloud versus On-Premise Considerations

The architectural choice between cloud-based and on-premise deployment for DSCSA compliance systems has significant implications for scalability, operational responsibility, and total cost of ownership. Cloud-based serialization and traceability platforms offer several advantages for DSCSA compliance: elastic scalability to handle peak data volumes during high-volume shipping periods, reduced infrastructure management burden because the cloud provider manages the underlying infrastructure, and built-in connectivity capabilities that simplify trading partner onboarding. On-premise deployments may be preferred by organizations with strict data sovereignty requirements, those with existing data center investments that provide favorable cost economics, or those that prefer to maintain direct control over system availability and performance. Many organizations adopt a hybrid approach, maintaining on-premise serialization systems at manufacturing sites for performance-critical packaging line integration while using cloud-based platforms for enterprise data management and trading partner connectivity.

Integration with Manufacturing Systems

The integration between the enterprise serialization platform and manufacturing site systems is a critical architectural challenge, particularly for organizations with multiple manufacturing sites, diverse packaging line equipment, and contract manufacturing relationships. At each manufacturing site, the serialization system must integrate with packaging line equipment for serial number printing and verification, with packaging line control systems for production order management and line clearance, and with site-level enterprise systems for batch and lot data. These integrations must be reliable and performant because any disruption to the serialization data flow at the packaging line level will directly affect production throughput. The integration architecture must also accommodate contract manufacturing organizations, which operate their own serialization systems and must exchange serialization data with the brand owner’s enterprise platform through standardized interfaces.

Data Retention and Archival

The DSCSA requires that transaction data be retained for a minimum of six years. Given the volume of package-level transaction data generated by a typical pharmaceutical manufacturer, the data retention requirement has significant implications for storage capacity, query performance, and data management strategy. Organizations must plan for the long-term growth of their serialization data stores and must implement archival strategies that maintain regulatory access to historical data while managing storage costs and query performance. The retention requirement also has implications for system migration and upgrade planning, because any future system replacement must include a strategy for migrating or maintaining access to the historical data stored in the current system.

Exceptions, Exemptions, and Waivers

The DSCSA includes several exceptions, exemptions, and waiver provisions that affect the scope of compliance requirements for specific product types, transaction types, and trading partner categories. IT leaders must understand these provisions because they define the boundary of the systems that must be built and the data that must be exchanged.

Product and Transaction Exemptions

Certain product categories are exempt from some or all DSCSA requirements. Blood and blood components, radioactive drugs, imaging drugs, certain intravenous products, medical gases, and homeopathic drugs are among the product categories that have specific exemptions. Certain transaction types are also exempt, including intra-company transfers between facilities owned by the same entity, product samples distributed under specific conditions, and certain emergency medical supplies. Additionally, products sold directly to patients by the manufacturer are exempt from the distribution-level traceability requirements, though they still require serialization. IT systems must be configured to accurately identify exempt products and transactions to avoid both unnecessary compliance burden for exempt items and compliance gaps for non-exempt items that are incorrectly classified.

Small Dispenser and Small Business Provisions

The DSCSA includes provisions that recognize the compliance burden on small dispensers and small businesses by providing extended timelines and reduced requirements for certain categories of trading partners. Small dispensers that fall below defined purchasing thresholds have additional time to implement electronic traceability capabilities. These provisions affect manufacturers and wholesale distributors because they must be able to support trading partners that are operating under different compliance timelines and may not yet be capable of full electronic data exchange. IT systems must be flexible enough to accommodate trading partners with varying levels of capability, potentially supporting both electronic and transitional data exchange methods during the extended compliance periods.

FDA Waiver Process

The DSCSA authorizes the FDA to grant waivers, exceptions, and exemptions from the requirements of the law when the FDA determines that the waiver is consistent with the public health protection objectives of the DSCSA. Organizations that face genuine technical or operational barriers to compliance within the statutory timelines can apply for waivers, though the FDA has indicated that waivers are intended for narrow, specific situations rather than broad relief from compliance obligations. IT leaders should be aware of the waiver process as a risk management tool, but should not rely on waivers as a compliance strategy. The waiver process is discretionary on the FDA’s part, and there is no guarantee that a waiver request will be granted or that the terms of a granted waiver will align with the organization’s preferred compliance approach.

FDA Enforcement Posture and Inspection Priorities

Understanding the FDA’s enforcement posture and inspection priorities helps IT leaders calibrate their compliance investments and focus resources on the areas of greatest regulatory risk. The FDA’s approach to DSCSA enforcement reflects both the statutory requirements and the practical realities of industry readiness.

Risk-Based Enforcement Approach

The FDA has indicated that its DSCSA enforcement approach will be risk-based, focusing on the compliance elements that have the greatest impact on patient safety and supply chain integrity. This risk-based approach suggests that the FDA will prioritize enforcement in several key areas. First, verification capabilities that enable the detection and removal of suspect and illegitimate products from the supply chain will be a primary enforcement focus because they directly protect patient safety. Second, the ability to trace products at the package level in response to FDA requests will be prioritized because this capability is essential for the agency’s ability to respond to drug supply chain emergencies and manage recalls effectively. Third, the completeness and accuracy of transaction data exchanged between trading partners will be assessed because data gaps and inaccuracies undermine the utility of the entire traceability system.

Inspection Readiness

DSCSA compliance is becoming an increasingly prominent element of FDA inspections of pharmaceutical manufacturers and wholesale distributors. Inspection readiness for DSCSA requires the ability to demonstrate the organization’s serialization and traceability capabilities, including the systems used, the data exchanged with trading partners, and the procedures for responding to verification requests and trace requests. Organizations should prepare for DSCSA-focused inspections by maintaining current documentation of their DSCSA compliance systems and processes, testing their ability to respond to trace requests within the timeframes expected by the FDA, reviewing the completeness and accuracy of their transaction data through periodic audits, and ensuring that their verification services are operational and capable of responding to verification requests from trading partners. The ability to demonstrate these capabilities during an inspection is as important as having the capabilities in place, and organizations should invest in inspection readiness preparation as a distinct component of their DSCSA compliance program.

Industry Benchmarking

IT leaders benefit from understanding how their organization’s DSCSA compliance maturity compares to the broader industry. Industry surveys and benchmarking studies provide useful data points on the percentage of transactions being exchanged electronically at the package level, the number of trading partners that have been onboarded for electronic data exchange, the time required to respond to verification requests and trace requests, and the level of automation versus manual intervention in DSCSA compliance processes. These benchmarks help IT leaders identify areas where their organization may be lagging behind industry peers and where investment in compliance capabilities would be most productive.

Solution Vendor Landscape

The DSCSA compliance solution market has matured significantly since the early phases of serialization implementation. The vendor landscape now includes established serialization platform providers, interoperability network operators, and specialized service providers that address specific aspects of the compliance challenge.

Enterprise Serialization and Traceability Platforms

Several enterprise software vendors have developed comprehensive serialization and traceability platforms that address the full scope of DSCSA compliance requirements. These platforms typically provide serial number management, EPCIS event generation, trading partner connectivity, verification services, and regulatory reporting capabilities in an integrated solution. The leading platforms have been deployed at scale across the pharmaceutical industry and have accumulated significant domain expertise in DSCSA compliance. When evaluating enterprise platforms, IT leaders should assess the platform’s track record of successful deployments in organizations of similar size and complexity, its scalability to handle the organization’s serial number volumes and trading partner count, the breadth and maturity of its trading partner connectivity capabilities, and the platform’s roadmap for supporting evolving DSCSA requirements and emerging standards such as GS1 Digital Link.

Interoperability Networks

Interoperability networks provide a shared infrastructure for exchanging DSCSA transaction data between trading partners. Rather than establishing point-to-point connections with each trading partner, organizations connect to the network and can exchange data with any other network member through the network’s routing and translation services. Interoperability networks reduce the trading partner onboarding burden because each trading partner only needs to establish a single connection to the network rather than individual connections with every trading partner. However, network-based connectivity introduces dependency on the network operator and may require organizations to conform to the network’s data format and process requirements. The value of an interoperability network increases with the number of trading partners that are connected to the network, creating network effects that favor the largest networks.

Contract Manufacturing Integration

Organizations that use contract manufacturing organizations for product manufacturing face additional complexity in their DSCSA compliance architecture. The CMO operates the serialization equipment and generates the initial serial number data, but the brand owner is responsible for the regulatory compliance of the product throughout the supply chain. This creates a data exchange requirement between the CMO’s serialization system and the brand owner’s enterprise serialization platform. The quality and timeliness of this data exchange is critical because any delays or errors in serial number data transfer from the CMO to the brand owner can prevent the brand owner from fulfilling verification requests and trade partner data exchange requirements. IT leaders should include CMO data integration in their DSCSA compliance architecture design and should establish clear data exchange specifications and service level agreements with each CMO partner.

Implementation Roadmap for Late Adopters

Organizations that have not yet achieved full DSCSA compliance face the challenge of compressing a multi-year implementation program into a shorter timeframe while the regulatory enforcement window is narrowing. A structured implementation roadmap can help these organizations prioritize their compliance investments and achieve the most impactful capabilities first.

Phase One: Foundation (Months One Through Six)

The first phase focuses on establishing the foundational capabilities that represent the minimum compliance baseline. This includes completing serialization deployment across all packaging lines if not already done, implementing or upgrading the enterprise serialization platform to support package-level data management, establishing electronic data exchange with the organization’s largest trading partners by volume, and deploying product identifier verification services that can respond to verification requests from downstream trading partners. The priority in this phase is to achieve functional capability with the trading partners that represent the largest share of the organization’s transaction volume, even if the data exchange is not yet fully optimized or automated.

Phase Two: Scale and Optimize (Months Six Through Eighteen)

The second phase focuses on expanding trading partner connectivity, improving data quality, and optimizing operational processes. This includes onboarding additional trading partners for electronic data exchange, implementing data quality monitoring and exception management processes, integrating EPCIS event generation with warehouse management and distribution systems, optimizing aggregation processes to ensure accurate hierarchy data through the distribution chain, and building the trace request response capability needed to respond to FDA inquiries. The goal of this phase is to achieve reliable, high-quality electronic data exchange with the majority of the organization’s trading partners and to establish the operational processes needed to sustain compliance on an ongoing basis.

Phase Three: Maturity and Strategic Value (Months Eighteen Through Thirty-Six)

The third phase focuses on achieving full compliance maturity and extracting strategic value from the serialization and traceability infrastructure. This includes completing trading partner onboarding for all remaining trading partners, implementing advanced analytics on serialization and traceability data to identify supply chain optimization opportunities, building enhanced recall management capabilities that leverage package-level traceability data for targeted recalls, and establishing continuous compliance monitoring that provides ongoing assurance of data quality and system performance. Organizations that reach this phase of maturity have not only satisfied their regulatory compliance obligations but have built a data infrastructure that provides strategic visibility into their supply chain operations.

Beyond Compliance: Strategic Value of Serialization Data

While DSCSA compliance is a regulatory mandate, the serialization and traceability infrastructure that it requires creates a data asset with significant strategic value that extends well beyond regulatory compliance. Forward-thinking IT leaders are designing their DSCSA systems not merely to satisfy regulatory requirements but to create a platform for supply chain intelligence and operational improvement.

Supply Chain Visibility

Package-level traceability data provides unprecedented visibility into the movement of products through the supply chain. By analyzing the EPCIS event data generated through DSCSA compliance processes, organizations can track the time products spend at each stage of the supply chain, identify distribution bottlenecks and inefficiencies, monitor channel inventory levels with greater granularity than traditional methods allow, and detect anomalous distribution patterns that may indicate diversion or other supply chain integrity issues. This visibility was not available before serialization and traceability systems were deployed, and it represents a genuine competitive advantage for organizations that invest in the analytics capabilities needed to extract insights from the data.

Targeted Recall Management

One of the most tangible operational benefits of package-level traceability is the ability to conduct highly targeted product recalls. Before serialization, product recalls were conducted at the lot level, requiring the recall of every package in an affected lot regardless of whether the specific packages had been distributed to the affected channel. With package-level traceability, organizations can identify the specific packages affected by a quality issue, determine exactly where those packages are in the supply chain, and target the recall to the specific locations that received the affected packages. This targeted approach reduces the cost and disruption of recalls, minimizes the impact on unaffected product, and improves the speed and effectiveness of the recall process.

Anti-Counterfeiting and Supply Chain Integrity

The package-level verification capabilities required by the DSCSA provide a powerful tool for detecting counterfeit and diverted pharmaceutical products. When every legitimate package has a unique, verifiable serial number and every transaction in the supply chain is documented in a continuous electronic record, it becomes significantly more difficult for counterfeit products to enter the legitimate supply chain undetected. Verification failures, where a serial number presented for verification does not match the manufacturer’s records, provide an early warning of potential counterfeiting activity. Anomalies in transaction data, such as products appearing in distribution channels that are inconsistent with the manufacturer’s authorized distribution network, can indicate diversion or other integrity issues. These supply chain integrity capabilities have value that extends beyond regulatory compliance to brand protection and patient safety assurance.

Data-Driven Supply Chain Optimization

The granular, real-time supply chain data generated by DSCSA compliance systems provides the foundation for advanced supply chain analytics and optimization. Organizations can use serialization data to analyze demand patterns at the package level, optimize inventory positioning across the distribution network, improve demand forecasting by incorporating real-time distribution data, and identify opportunities to reduce distribution costs through route optimization and channel consolidation. The organizations that derive the greatest strategic value from their DSCSA compliance investments will be those that treat serialization data not as a regulatory compliance byproduct but as a strategic data asset that informs supply chain decision-making.

The DSCSA enforcement landscape in 2026 represents a critical inflection point for pharmaceutical IT leaders. The stabilization period that followed the November 2024 compliance milestone is narrowing, and the FDA’s enforcement posture is shifting from broad enforcement discretion toward increasingly specific compliance expectations. Organizations that have achieved foundational compliance capabilities, including serialization, verification services, and electronic data exchange with major trading partners, are well-positioned to complete their compliance programs as enforcement expectations tighten. Those that have delayed investment in DSCSA compliance systems face an increasingly compressed timeline and an escalating regulatory risk profile. The IT architecture decisions made now will determine not only whether the organization achieves compliance but whether it captures the strategic value that package-level supply chain traceability data can deliver. IT leaders who approach DSCSA compliance as a strategic infrastructure investment rather than a regulatory cost will build capabilities that serve the organization long after the compliance deadline has passed.